Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
Add more filters

Publication year range
1.
Ann Neurol ; 95(6): 1058-1068, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38466157

ABSTRACT

OBJECTIVE: Along with the known effects of stress on brain structure and inflammatory processes, increasing evidence suggest a role of chronic stress in the pathogenesis of Alzheimer's disease (AD). We investigated the association of accumulated stressful life events (SLEs) with AD pathologies, neuroinflammation, and gray matter (GM) volume among cognitively unimpaired (CU) individuals at heightened risk of AD. METHODS: This cross-sectional cohort study included 1,290 CU participants (aged 48-77) from the ALFA cohort with SLE, lumbar puncture (n = 393), and/or structural magnetic resonance imaging (n = 1,234) assessments. Using multiple regression analyses, we examined the associations of total SLEs with cerebrospinal fluid (1) phosphorylated (p)-tau181 and Aß1-42/1-40 ratio, (2) interleukin 6 (IL-6), and (3) GM volumes voxel-wise. Further, we performed stratified and interaction analyses with sex, history of psychiatric disease, and evaluated SLEs during specific life periods. RESULTS: Within the whole sample, only childhood and midlife SLEs, but not total SLEs, were associated with AD pathophysiology and neuroinflammation. Among those with a history of psychiatric disease SLEs were associated with higher p-tau181 and IL-6. Participants with history of psychiatric disease and men, showed lower Aß1-42/1-40 with higher SLEs. Participants with history of psychiatric disease and women showed reduced GM volumes in somatic regions and prefrontal and limbic regions, respectively. INTERPRETATION: We did not find evidence supporting the association of total SLEs with AD, neuroinflammation, and atrophy pathways. Instead, the associations appear to be contingent on events occurring during early and midlife, sex and history of psychiatric disease. ANN NEUROL 2024;95:1058-1068.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Brain , Neuroinflammatory Diseases , tau Proteins , Humans , Alzheimer Disease/pathology , Alzheimer Disease/diagnostic imaging , Female , Male , Aged , Middle Aged , Cross-Sectional Studies , Cohort Studies , Brain/pathology , Brain/diagnostic imaging , Neuroinflammatory Diseases/pathology , Neuroinflammatory Diseases/diagnostic imaging , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Peptides/metabolism , tau Proteins/cerebrospinal fluid , Magnetic Resonance Imaging , Stress, Psychological , Gray Matter/pathology , Gray Matter/diagnostic imaging , Interleukin-6/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid
2.
J Neurovirol ; 30(2): 165-175, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38575831

ABSTRACT

Persistent inflammation is described in people with HIV (PWH) on antiretroviral treatment (ART). Early ART initiation is associated with reduced inflammation. We aimed to evaluate neuroinflammation, using translocator protein (TSPO) [11C]PBR28 PET neuroimaging in PWH who initiated ART during acute HIV (aPWH) versus chronic HIV infection (cPWH) versus a control population. This was a cross-sectional, observational study. All participants underwent [11C]PBR28 PET-CT neuroimaging. Using a two-tissue compartment model, total volume of distribution (VT) and distribution volume ratios (DVR) using cortical grey matter as a pseudo-reference region at 20 regions of interest (ROIs) were calculated. Differences in VT and DVR were compared between groups using the Kruskall-Wallis test. Seventeen neuro-asymptomatic male PWH on ART (9 aPWH, 8 cPWH) and 8 male control participants (CPs) were included. Median (interquartile range, IQR) age was 40 (30, 46), 44 (41, 47) and 21 (20, 25) years in aPWH, cPWH and CPs, respectively. Median (IQR) CD4 (cells/µL) and CD4:CD8 were 687 (652, 1014) and 1.37 (1.24, 1.42), and 700 (500, 720) and 0.67 (0.64, 0.82) in aPWH and cPWH, respectively. Overall, no significant difference in VT and DVR were observed between the three groups at any ROIs. cPWH demonstrated a trend towards higher mean VT compared with aPWH and CPs at most ROIs. No significant differences in neuroinflammation, using [11C]PBR28 binding as a proxy, were identified between cPWH, aPWH and CPs. A trend towards lower absolute [11C]PBR28 binding was seen amongst aPWH and CPs, suggesting early ART may mitigate neuroinflammation.


Subject(s)
HIV Infections , Neuroinflammatory Diseases , Receptors, GABA , Humans , Male , Receptors, GABA/metabolism , HIV Infections/drug therapy , HIV Infections/diagnostic imaging , HIV Infections/metabolism , HIV Infections/virology , Adult , Middle Aged , Cross-Sectional Studies , Female , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/drug therapy , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/metabolism , Neuroinflammatory Diseases/virology , Chronic Disease , Positron Emission Tomography Computed Tomography/methods , Pyridines/therapeutic use , Carbon Radioisotopes , Brain/diagnostic imaging , Brain/drug effects , Brain/metabolism , Brain/virology , Gray Matter/diagnostic imaging , Gray Matter/metabolism , Gray Matter/drug effects , Gray Matter/virology , Gray Matter/pathology , Anti-Retroviral Agents/therapeutic use , Anti-HIV Agents/therapeutic use , Positron-Emission Tomography/methods , Radiopharmaceuticals
3.
Brain Behav Immun ; 119: 978-988, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38761819

ABSTRACT

BACKGROUND: Neuroinflammation affects brain tissue integrity in multiple sclerosis (MS) and may have a role in major depressive disorder (MDD). Whether advanced magnetic resonance imaging characteristics of the gray-to-white matter border serve as proxy of neuroinflammatory activity in MDD and MS remain unknown. METHODS: We included 684 participants (132 MDD patients with recurrent depressive episodes (RDE), 70 MDD patients with a single depressive episode (SDE), 222 MS patients without depressive symptoms (nMS), 58 MS patients with depressive symptoms (dMS), and 202 healthy controls (HC)). 3 T-T1w MRI-derived gray-to-white matter contrast (GWc) was used to reconstruct and characterize connectivity alterations of GWc-covariance networks by means of modularity, clustering coefficient, and degree. A cross-validated support vector machine was used to test the ability of GWc to stratify groups according to their depression symptoms, measured with BDI, at the single-subject level in MS and MDD independently. FINDINGS: MS and MDD patients showed increased modularity (ANOVA partial-η2 = 0.3) and clustering (partial-η2 = 0.1) compared to HC. In the subgroups, a linear trend analysis attested a gradient of modularity increases in the form: HC, dMS, nMS, SDE, and RDE (ANOVA partial-η2 = 0.28, p < 0.001) while this trend was less evident for clustering coefficient. Reduced morphological integrity (GWc) was seen in patients with increased depressive symptoms (partial-η2 = 0.42, P < 0.001) and was associated with depression scores across patient groups (r = -0.2, P < 0.001). Depressive symptoms in MS were robustly classified (88 %). CONCLUSIONS: Similar structural network alterations in MDD and MS exist, suggesting possible common inflammatory events like demyelination, neuroinflammation that are caught by GWc analyses. These alterations may vary depending on the severity of symptoms and in the case of MS may elucidate the occurrence of comorbid depression.


Subject(s)
Brain , Depression , Depressive Disorder, Major , Gray Matter , Inflammation , Magnetic Resonance Imaging , Multiple Sclerosis , White Matter , Humans , Female , Male , Adult , Magnetic Resonance Imaging/methods , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/pathology , Multiple Sclerosis/psychology , Multiple Sclerosis/complications , Multiple Sclerosis/physiopathology , Middle Aged , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/physiopathology , Brain/diagnostic imaging , Brain/pathology , White Matter/diagnostic imaging , White Matter/pathology , Depression/physiopathology , Gray Matter/pathology , Gray Matter/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging
4.
Brain Behav Immun ; 119: 713-723, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38642615

ABSTRACT

The COVID-19 pandemic caused by SARS-CoV-2 has triggered a consequential public health crisis of post-acute sequelae of COVID-19 (PASC), sometimes referred to as long COVID. The mechanisms of the heterogeneous persistent symptoms and signs that comprise PASC are under investigation, and several studies have pointed to the central nervous and vascular systems as being potential sites of dysfunction. In the current study, we recruited individuals with PASC with diverse symptoms, and examined the relationship between neuroinflammation and circulating markers of vascular dysfunction. We used [11C]PBR28 PET neuroimaging, a marker of neuroinflammation, to compare 12 PASC individuals versus 43 normative healthy controls. We found significantly increased neuroinflammation in PASC versus controls across a wide swath of brain regions including midcingulate and anterior cingulate cortex, corpus callosum, thalamus, basal ganglia, and at the boundaries of ventricles. We also collected and analyzed peripheral blood plasma from the PASC individuals and found significant positive correlations between neuroinflammation and several circulating analytes related to vascular dysfunction. These results suggest that an interaction between neuroinflammation and vascular health may contribute to common symptoms of PASC.


Subject(s)
Brain , COVID-19 , Neuroinflammatory Diseases , Positron-Emission Tomography , SARS-CoV-2 , Humans , COVID-19/diagnostic imaging , COVID-19/complications , Male , Positron-Emission Tomography/methods , Female , Middle Aged , Adult , Neuroinflammatory Diseases/diagnostic imaging , Brain/diagnostic imaging , Brain/metabolism , Post-Acute COVID-19 Syndrome , Vascular Diseases/diagnostic imaging , Aged , Pyridines , Pyrimidines
5.
Eur J Neurol ; 31(7): e16284, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38506182

ABSTRACT

OBJECTIVE: This study was undertaken to provide a comprehensive review of neuroimaging characteristics and corresponding clinical phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A), a rare but severe neuroinflammatory disorder, to facilitate early diagnosis and appropriate treatment. METHODS: A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis)-conforming systematic review and meta-analysis was performed on all available data from January 2016 to June 2023. Clinical and neuroimaging phenotypes were extracted for both adult and paediatric forms. RESULTS: A total of 93 studies with 681 cases (55% males; median age = 46, range = 1-103 years) were included. Of these, 13 studies with a total of 535 cases were eligible for the meta-analysis. Clinically, GFAP-A was often preceded by a viral prodromal state (45% of cases) and manifested as meningitis, encephalitis, and/or myelitis. The most common symptoms were headache, fever, and movement disturbances. Coexisting autoantibodies (45%) and neoplasms (18%) were relatively frequent. Corticosteroid treatment resulted in partial/complete remission in a majority of cases (83%). Neuroimaging often revealed T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities (74%) as well as perivascular (45%) and/or leptomeningeal (30%) enhancement. Spinal cord abnormalities were also frequent (49%), most commonly manifesting as longitudinally extensive myelitis. There were 88 paediatric cases; they had less prominent neuroimaging findings with lower frequencies of both T2/FLAIR hyperintensities (38%) and contrast enhancement (19%). CONCLUSIONS: This systematic review and meta-analysis provide high-level evidence for clinical and imaging phenotypes of GFAP-A, which will benefit the identification and clinical workup of suspected cases. Differential diagnostic cues to distinguish GFAP-A from common clinical and imaging mimics are provided as well as suitable magnetic resonance imaging protocol recommendations.


Subject(s)
Glial Fibrillary Acidic Protein , Neuroimaging , Humans , Astrocytes/pathology , Autoantibodies/blood , Autoimmune Diseases of the Nervous System/diagnostic imaging , Autoimmune Diseases of the Nervous System/immunology , Glial Fibrillary Acidic Protein/immunology , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/immunology , Phenotype
6.
Proc Natl Acad Sci U S A ; 118(36)2021 09 07.
Article in English | MEDLINE | ID: mdl-34479997

ABSTRACT

Neuroinflammation is a pathophysiological hallmark of multiple sclerosis and has a close mechanistic link to neurodegeneration. Although this link is potentially targetable, robust translatable models to reliably quantify and track neuroinflammation in both mice and humans are lacking. The choroid plexus (ChP) plays a pivotal role in regulating the trafficking of immune cells from the brain parenchyma into the cerebrospinal fluid (CSF) and has recently attracted attention as a key structure in the initiation of inflammatory brain responses. In a translational framework, we here address the integrity and multidimensional characteristics of the ChP under inflammatory conditions and question whether ChP volumes could act as an interspecies marker of neuroinflammation that closely interrelates with functional impairment. Therefore, we explore ChP characteristics in neuroinflammation in patients with multiple sclerosis and in two experimental mouse models, cuprizone diet-related demyelination and experimental autoimmune encephalomyelitis. We demonstrate that ChP enlargement-reconstructed from MRI-is highly associated with acute disease activity, both in the studied mouse models and in humans. A close dependency of ChP integrity and molecular signatures of neuroinflammation is shown in the performed transcriptomic analyses. Moreover, pharmacological modulation of the blood-CSF barrier with natalizumab prevents an increase of the ChP volume. ChP enlargement is strongly linked to emerging functional impairment as depicted in the mouse models and in multiple sclerosis patients. Our findings identify ChP characteristics as robust and translatable hallmarks of acute and ongoing neuroinflammatory activity in mice and humans that could serve as a promising interspecies marker for translational and reverse-translational approaches.


Subject(s)
Choroid Plexus/diagnostic imaging , Multiple Sclerosis/physiopathology , Neuroinflammatory Diseases/diagnostic imaging , Adult , Animals , Blood-Brain Barrier/physiology , Brain/physiology , Choroid Plexus/immunology , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/physiopathology , Female , Humans , Magnetic Resonance Imaging/methods , Male , Mice , Mice, Inbred C57BL , Multiple Sclerosis/diagnostic imaging , Proteomics/methods
7.
Bioorg Med Chem ; 83: 117233, 2023 04 01.
Article in English | MEDLINE | ID: mdl-36933438

ABSTRACT

We report the design, synthesis and evaluation of five o­aminopyridyl alkynyl derivatives as colony-stimulating factor 1 receptor (CSF-1R) ligands. Compounds 4 and 5 with the fluoroethoxy group at the meta- or para-position of the phenyl ring possessed nanomolar inhibitory potency against CSF-1R with IC50 values of 7.6 nM and 2.3 nM, respectively. Radioligands [18F]4 and [18F]5 were obtained in radiochemical yields of 17.2 ± 5.3% (n = 5, decay-corrected) and 14.0 ± 4.3% (n = 4, decay-corrected), with radiochemical purity of > 99% and molar activity of 9-12 GBq/µmol (n = 5) and 6-8 GBq/µmol (n = 4), respectively. In biodistribution studies, radioligands [18F]4 and [18F]5 showed moderate brain uptake in male ICR mice with 1.52 ± 0.15 and 0.91 ± 0.07% ID/g, respectively, at 15 min. Metabolic stability studies in mouse brain revealed that [18F]4 exhibited high stability while [18F]5 suffered from low stability. Higher accumulation of [18F]4 in the brain of lipopolysaccharide (LPS)-treated mice was observed, and further pretreatment of BLZ945 or CPPC led to remarkable reduction, indicating specific binding of [18F]4 to CSF-1R.


Subject(s)
Aminopyridines , Fluorine Radioisotopes , Neuroinflammatory Diseases , Positron-Emission Tomography , Receptors, Granulocyte-Macrophage Colony-Stimulating Factor , Animals , Male , Mice , Fluorine Radioisotopes/chemistry , Mice, Inbred ICR , Neuroinflammatory Diseases/diagnostic imaging , Positron-Emission Tomography/methods , Tissue Distribution , Aminopyridines/chemistry , Aminopyridines/pharmacology , Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/chemistry
8.
Eur J Nucl Med Mol Imaging ; 49(9): 3162-3172, 2022 07.
Article in English | MEDLINE | ID: mdl-35165788

ABSTRACT

PURPOSE: Chronic traumatic encephalopathy refers to a neurodegenerative disease resulting from repetitive head injury of participants in contact sports. Similar to other neurodegenerative diseases, neuroinflammation is thought to play a role in the onset and progression of the disease. Limited knowledge is available regarding the neuroinflammatory consequences of repetitive head injury in currently active contact sports athletes. PET imaging of the 18-kDa translocator protein (TSPO) allows quantification of microglial activation in vivo, a marker of neuroinflammation. METHODS: Eleven rank A kickboxers and 11 age-matched controls underwent TSPO PET using [11C]-PK11195, anatomical MRI, diffusion tensor imaging, and neuropsychological testing. Relevant imaging parameters were derived and correlated with the outcomes of the neuropsychological testing. RESULTS: On a group level, no statistically significant differences were detected in non-displaceable binding potential (BPND) using PET. Individually, 3 kickboxers showed increased BPNDs in widespread regions of the brain without a correlation with other modalities. Increased FA was observed in the superior corona radiata bilaterally. DTI parameters in other regions did not differ between groups. CONCLUSION: Despite negative results on a group level, individual results suggest that neuroinflammation may be present as a consequence of repetitive head injury in active kickboxers. Future studies using a longitudinal design may determine whether the observed TSPO upregulation is related to the future development of neuropsychiatric symptoms.


Subject(s)
Athletic Injuries , Craniocerebral Trauma , Neurodegenerative Diseases , Neuroinflammatory Diseases , Athletic Injuries/diagnostic imaging , Brain/metabolism , Craniocerebral Trauma/diagnostic imaging , Craniocerebral Trauma/metabolism , Diffusion Tensor Imaging , Humans , Martial Arts/injuries , Neurodegenerative Diseases/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging , Positron-Emission Tomography/methods , Receptors, GABA/metabolism
9.
Clin Exp Immunol ; 206(3): 325-345, 2021 12.
Article in English | MEDLINE | ID: mdl-34596237

ABSTRACT

Since the first studies of the nervous system by the Nobel laureates Camillo Golgi and Santiago Ramon y Cajal using simple dyes and conventional light microscopes, microscopy has come a long way to the most recent techniques that make it possible to perform images in live cells and animals in health and disease. Many pathological conditions of the central nervous system have already been linked to inflammatory responses. In this scenario, several available markers and techniques can help imaging and unveil the neuroinflammatory process. Moreover, microscopy imaging techniques have become even more necessary to validate the large quantity of data generated in the era of 'omics'. This review aims to highlight how to assess neuroinflammation by using microscopy as a tool to provide specific details about the cell's architecture during neuroinflammatory conditions. First, we describe specific markers that have been used in light microscopy studies and that are widely applied to unravel and describe neuroinflammatory mechanisms in distinct conditions. Then, we discuss some important methodologies that facilitate the imaging of these markers, such as immunohistochemistry and immunofluorescence techniques. Emphasis will be given to studies using two-photon microscopy, an approach that revolutionized the real-time assessment of neuroinflammatory processes. Finally, some studies integrating omics with microscopy will be presented. The fusion of these techniques is developing, but the high amount of data generated from these applications will certainly improve comprehension of the molecular mechanisms involved in neuroinflammation.


Subject(s)
Central Nervous System/diagnostic imaging , Microscopy, Fluorescence/methods , Neuroinflammatory Diseases/diagnostic imaging , Optical Imaging/methods , Fluorescent Antibody Technique/methods , Humans , Immunohistochemistry/methods , Neuroimaging/methods
10.
Clin Exp Immunol ; 206(3): 301-313, 2021 12.
Article in English | MEDLINE | ID: mdl-34510431

ABSTRACT

Neuropathology studies of amyotrophic lateral sclerosis (ALS) and animal models of ALS reveal a strong association between aberrant protein accumulation and motor neurone damage, as well as activated microglia and astrocytes. While the role of neuroinflammation in the pathology of ALS is unclear, imaging studies of the central nervous system (CNS) support the idea that innate immune activation occurs early in disease in both humans and rodent models of ALS. In addition, emerging studies also reveal changes in monocytes, macrophages and lymphocytes in peripheral blood as well as at the neuromuscular junction. To more clearly understand the association of neuroinflammation (innate and adaptive) with disease progression, the use of biomarkers and imaging modalities allow monitoring of immune parameters in the disease process. Such approaches are important for patient stratification, selection and inclusion in clinical trials, as well as to provide readouts of response to therapy. Here, we discuss the different imaging modalities, e.g. magnetic resonance imaging, magnetic resonance spectroscopy and positron emission tomography as well as other approaches, including biomarkers of inflammation in ALS, that aid the understanding of the underlying immune mechanisms associated with motor neurone degeneration in ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/diagnostic imaging , Amyotrophic Lateral Sclerosis/pathology , Brain/diagnostic imaging , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy/methods , Positron-Emission Tomography/methods , Amyotrophic Lateral Sclerosis/immunology , Animals , Brain/pathology , Disease Models, Animal , Disease Progression , Humans , Inflammation/pathology , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/pathology
11.
Clin Exp Immunol ; 206(3): 282-300, 2021 12.
Article in English | MEDLINE | ID: mdl-34331705

ABSTRACT

There is increasing evidence showing the heterogeneity of microglia activation in neuroinflammatory and neurodegenerative diseases. It has been hypothesized that pro-inflammatory microglia are detrimental and contribute to disease progression, while anti-inflammatory microglia play a role in damage repair and remission. The development of therapeutics targeting the deleterious glial activity and modulating it into a regenerative phenotype relies heavily upon a clearer understanding of the microglia dynamics during disease progression and the ability to monitor therapeutic outcome in vivo. To that end, molecular imaging techniques are required to assess microglia dynamics and study their role in disease progression as well as to evaluate the outcome of therapeutic interventions. Positron emission tomography (PET) is such a molecular imaging technique, and provides unique capabilities for non-invasive quantification of neuroinflammation and has the potential to discriminate between microglia phenotypes and define their role in the disease process. However, several obstacles limit the possibility for selective in vivo imaging of microglia phenotypes mainly related to the poor characterization of specific targets that distinguish the two ends of the microglia activation spectrum and lack of suitable tracers. PET tracers targeting translocator protein 18 kDa (TSPO) have been extensively explored, but despite the success in evaluating neuroinflammation they failed to discriminate between microglia activation statuses. In this review, we highlight the current knowledge on the microglia phenotypes in the major neuroinflammatory and neurodegenerative diseases. We also discuss the current and emerging PET imaging targets, the tracers and their potential in discriminating between the pro- and anti-inflammatory microglia activation states.


Subject(s)
Microglia/pathology , Neurodegenerative Diseases/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging , Positron-Emission Tomography/methods , Humans , Neurodegenerative Diseases/pathology , Neuroinflammatory Diseases/pathology , Prostaglandin-Endoperoxide Synthases/analysis , Radioactive Tracers , Receptor, Cannabinoid, CB2/analysis , Receptor, Macrophage Colony-Stimulating Factor/analysis , Receptors, GABA/analysis , Receptors, Purinergic P2X7/analysis , Receptors, Purinergic P2Y12/analysis
12.
Clin Exp Immunol ; 206(3): 248-250, 2021 12.
Article in English | MEDLINE | ID: mdl-34726266

ABSTRACT

Innate and adaptive immune responses in the central nervous system (CNS) play critical roles in the pathogenesis of neurological diseases. In the first of a two-part special issue, leading researchers discuss how imaging modalities are used to monitor immune responses in several neurodegenerative diseases and glioblastoma and brain metastases. While comparative studies in humans between imaging and pathology are biased towards the end stage of disease, animal models can inform regarding how immune responses change with disease progression and as a result of treatment regimens. Magnetic resonance imaging (MRI) and positron emission tomography (PET) are frequently used to image disease progression, and the articles indicate how one or more of these modalities have been applied to specific neuroimmune diseases. In addition, advanced microscopical imaging using two-dimensional photon microscopy and in vitro live cell imaging have also been applied to animal models. In this special issue (Parts 1 and 2), as well as the imaging modalities mentioned, several articles discuss biomarkers of disease and microscopical studies that have enabled characterization of immune responses. Future developments of imaging modalities should enable tracking of specific subsets of immune cells during disease allowing longitudinal monitoring of immune responses. These new approaches will be critical to more effectively monitor and thus target specific cell subsets for therapeutic interventions which may be applicable to a range of neurological diseases.


Subject(s)
Adaptive Immunity/immunology , Central Nervous System/diagnostic imaging , Glioblastoma/diagnostic imaging , Immunity, Innate/immunology , Neurodegenerative Diseases/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging , Biomarkers/analysis , Disease Progression , Glioblastoma/pathology , Humans , Magnetic Resonance Imaging , Neurodegenerative Diseases/immunology , Neurodegenerative Diseases/pathology , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/pathology , Positron-Emission Tomography , Tomography, Optical Coherence
13.
Ultrasound Med Biol ; 50(6): 961-968, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38685265

ABSTRACT

OBJECTIVE: To date there have been no studies exploring the potential for neuroinflammation as an intracranial bio-effect associated with diagnostic ultrasound during neonatal cranial scans in a mammalian in vivo model. The study described here was aimed at investigating the effects of B-mode and Doppler mode ultrasound on inflammation in the rat brain. METHODS: Twelve Wistar rats (7-9 wk old) were divided into a control group and an ultrasound-exposed group (n = 6/group). A craniotomy was performed, followed by 10 min of B-mode and spectral Doppler interrogation of the middle cerebral artery. The control group was subjected to sham treatment, with the transducer held stationary over the craniotomy site, but the ultrasound machine switched off. Animals were euthanized 48 h after exposure, and the brains formalin fixed for immunohistochemical analysis using allograft inflammatory factor 1 (IBA-1) and glial fibrillary acidic protein (GFAP) as markers of microglia and astrocytes, respectively. The numbers of IBA-1- and GFAP-immunoreactive cells were manually counted and expressed as areal density (cells/mm2). Results were analyzed using Student's unpaired t-test and one-way repeated-measures analysis of variance. RESULTS: The ultrasound-exposed brain exhibited significant increases in IBA-1 and GFAP immunoreactive cell density in all regions of B-mode and Doppler mode exposure compared with the control group (p < 0.001). CONCLUSION: Ten minutes of B-mode and Doppler mode ultrasound may induce neuroinflammatory changes in the rat brain. This suggests that exposure of brain tissue to current diagnostic ultrasound intensities may not be completely without risk.


Subject(s)
Brain , Neuroinflammatory Diseases , Rats, Wistar , Animals , Rats , Brain/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging , Male
14.
Neurol Neuroimmunol Neuroinflamm ; 11(5): e200294, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39047207

ABSTRACT

OBJECTIVES: To present 4 patients with Erdheim-Chester disease (ECD) based on clinical, radiologic, histopathologic, and molecular genetic findings who had enhancing brainstem lesions and were initially believed to have chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). METHODS: Case series. RESULTS: Although patients with ECD can demonstrate clinical and imaging features similar to CLIPPERS, refractoriness to corticosteroids, lack of fulfillment of specific MRI criteria (i.e., enhancing lesions >3 mm, T2 abnormalities that exceed areas of T1 postgadolinium enhancement), and systemic findings such as "hairy kidney" appearance and metadiaphyseal osteosclerosis on 18F-fluorodeoxyglucose PET-CT help discriminate it from CLIPPERS. DISCUSSION: ECD is a histiocytic neoplasm characterized by multiorgan infiltration of clonal histiocytes carrying activating variants of the MAPK-ERK pathway. Neurologic involvement occurs in up to 40% of ECD with frequent brainstem lesions that can mimic acquired neuroinflammatory disorders, such as CLIPPERS. ECD is an important CLIPPERS mimic with distinct pathophysiology and targeted treatments. We highlight the need to consider histiocytic disorders among other alternate diagnoses when findings are not classic for CLIPPERS.


Subject(s)
Erdheim-Chester Disease , Humans , Erdheim-Chester Disease/diagnosis , Erdheim-Chester Disease/genetics , Middle Aged , Male , Female , Diagnosis, Differential , Aged , Positron Emission Tomography Computed Tomography , Magnetic Resonance Imaging , Adult , Neuroinflammatory Diseases/diagnosis , Neuroinflammatory Diseases/diagnostic imaging
15.
Eur Radiol Exp ; 8(1): 82, 2024 Jul 24.
Article in English | MEDLINE | ID: mdl-39046630

ABSTRACT

BACKGROUND: This study aimed to investigate the long-term effects of repetitive mild traumatic brain injury (rmTBI) with varying inter-injury intervals by measuring diffusion tensor metrics, including mean diffusivity (MD), fractional anisotropy (FA), and diffusion magnitude (L) and pure anisotropy (q). METHODS: Eighteen rats were randomly divided into three groups: short-interval rmTBI (n = 6), long-interval rmTBI (n = 6), and sham controls (n = 6). MD, FA, L, and q values were analyzed from longitudinal diffusion tensor imaging at days 50 and 90 after rmTBI. Immunohistochemical staining against neurons, astrocytes, microglia, and myelin was performed. Analysis of variance, Pearson correlation coefficient, and simple linear regression model were used. RESULTS: At day 50 post-rmTBI, lower cortical FA and q values were shown in the short-interval group (p ≤ 0.038). In contrast, higher FA and q values were shown for the long-interval group (p ≤ 0.039) in the corpus callosum. In the ipsilesional external capsule and internal capsule, no significant changes were found in FA, while lower L and q values were shown in the short-interval group (p ≤ 0.028) at day 90. The q values in the external capsule and internal capsule were negatively correlated with the number of microglial cells and the total number of astroglial cells (p ≤ 0.035). CONCLUSION: Tensor scalar measurements, such as L and q values, are sensitive to exacerbated chronic injury induced by rmTBI with shorter inter-injury intervals and reflect long-term astrogliosis induced by the cumulative injury. RELEVANCE STATEMENT: Tensor scalar measurements, including L and q values, are potential DTI metrics for detecting long-term and subtle injury following rmTBI; in particular, q values may be used for quantifying remote white matter (WM) changes following rmTBI. KEY POINTS: The alteration of L and q values was demonstrated after chronic repetitive mild traumatic brain injury. Changing q values were observed in the impact site and remote WM. The lower q values in the remote WM were associated with astrogliosis.


Subject(s)
Brain Concussion , Diffusion Tensor Imaging , Rats, Sprague-Dawley , Animals , Diffusion Tensor Imaging/methods , Rats , Male , Brain Concussion/diagnostic imaging , Brain Concussion/complications , Anisotropy , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/etiology
16.
Medicine (Baltimore) ; 103(18): e38086, 2024 May 03.
Article in English | MEDLINE | ID: mdl-38701247

ABSTRACT

BACKGROUND: Dementia is a major public health challenge for aging societies worldwide. Neuroinflammation is thought to be a key factor in dementia development. The aim of this study was to comprehensively assess translocator protein (TSPO) expression by positron emission tomography (PET) imaging to reveal the characteristics of neuroinflammation in dementia. METHODS: We used a meta-analysis to retrieve literature on TSPO expression in dementia using PET imaging technology, including but not limited to the quality of the study design, sample size, and the type of TSPO ligand used in the study. For the included studies, we extracted key data, including TSPO expression levels, clinical characteristics of the study participants, and specific information on brain regions. Meta-analysis was performed using R software to assess the relationship between TSPO expression and dementia. RESULTS: After screening, 12 studies that met the criteria were included. The results of the meta-analysis showed that the expression level of TSPO was significantly elevated in patients with dementia, especially in the hippocampal region. The OR in the hippocampus was 1.50 with a 95% CI of 1.09 to 1.25, indicating a significant increase in the expression of TSPO in this region compared to controls. Elevated levels of inflammation in the prefrontal lobe and cingulate gyrus are associated with cognitive impairment in patients. This was despite an OR of 1.00 in the anterior cingulate gyrus, indicating that TSPO expression in this region did not correlate significantly with the findings. The overall heterogeneity test showed I² = 51%, indicating moderate heterogeneity. CONCLUSION: This study summarizes the existing literature on TSPO expression in specific regions of the brain in patients with dementia, and also provides some preliminary evidence on the possible association between neuroinflammation and dementia. However, the heterogeneity of results and limitations of the study suggest that we need to interpret these findings with caution. Future studies need to adopt a more rigorous and consistent methodological design to more accurately assess the role of neuroinflammation in dementia, thereby providing a more reliable evidence base for understanding pathological mechanisms and developing potential therapeutic strategies.


Subject(s)
Dementia , Neuroinflammatory Diseases , Positron-Emission Tomography , Receptors, GABA , Humans , Positron-Emission Tomography/methods , Dementia/diagnostic imaging , Dementia/metabolism , Receptors, GABA/metabolism , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/metabolism , Brain/diagnostic imaging , Brain/metabolism
17.
Adv Neurobiol ; 37: 65-80, 2024.
Article in English | MEDLINE | ID: mdl-39207687

ABSTRACT

The first line of defense for the central nervous system (CNS) against injury or disease is provided by microglia. Microglia were long believed to stay in a dormant/resting state, reacting only to injury or disease. This view changed dramatically with the development of modern imaging techniques that allowed the study of microglial behavior in the intact brain over time, to reveal the dynamic nature of their responses. Over the past two decades, in vivo imaging using multiphoton microscopy has revealed numerous new functions of microglia in the developing, adult, aged, injured, and diseased CNS. As the most dynamic cells in the brain, microglia continuously contact all structures and cell types, such as glial and vascular cells, neuronal cell bodies, axons, dendrites, and dendritic spines, and are believed to play a central role in sculpting neuronal networks throughout life. Following trauma, or in neurodegenerative or neuroinflammatory diseases, microglial responses range from protective to harmful, underscoring the need to better understand their diverse roles and states in different pathological conditions. In this chapter, we introduce multiphoton microscopy and discuss recent advances in structural and functional imaging technologies that have expanded our toolbox to study microglial states and behaviors in new ways and depths. We also discuss relevant mouse models available for in vivo imaging studies of microglia and review how such studies are constantly refining our understanding of the multifaceted role of microglia in the healthy and diseased CNS.


Subject(s)
Microglia , Microglia/metabolism , Microglia/pathology , Animals , Humans , Microscopy, Fluorescence, Multiphoton , Brain/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/pathology , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/pathology
18.
Adv Neurobiol ; 37: 579-589, 2024.
Article in English | MEDLINE | ID: mdl-39207714

ABSTRACT

Microglia, the resident immune cells of the central nervous system (CNS) play a key role in regulating and maintaining homeostasis in the brain. However, the CNS is also vulnerable to infections and inflammatory processes. In response to CNS perturbations, microglia become reactive, notably with expression of the translocator protein (TSPO), primarily on their outer mitochondrial membrane. Despite TSPO being commonly used as a marker for microglia, it is also present in other cell types such as astrocytes. Positron emission tomography (PET) ligands that target the TSPO enable the noninvasive detection and quantification of glial reactivity. While some limitations were raised, TSPO PET remains an attractive biomarker of CNS infection and inflammation. This book chapter delves into the development and application of microglial PET imaging with a focus on the TSPO PET. First, we provide an overview of the evolution of TSPO PET radioligands from first-generation to second-generation ligands and their applications in studying neuroinflammation (or CNS inflammation). Subsequently, we discuss the limitations and challenges associated with TSPO PET. Then we go on to explore non-TSPO targets for microglial PET imaging. Finally, we conclude with future directions for research and clinical practice in this field.


Subject(s)
Microglia , Neuroinflammatory Diseases , Positron-Emission Tomography , Receptors, GABA , Microglia/metabolism , Positron-Emission Tomography/methods , Humans , Receptors, GABA/metabolism , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/metabolism , Animals , Radiopharmaceuticals , Brain/diagnostic imaging , Brain/metabolism , Ligands
19.
J Clin Invest ; 134(11)2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38828729

ABSTRACT

Increasing evidence suggests a role of neuroinflammation in substance use disorders (SUDs). This Review presents findings from neuroimaging studies assessing brain markers of inflammation in vivo in individuals with SUDs. Most studies investigated the translocator protein 18 kDa (TSPO) using PET; neuroimmune markers myo-inositol, choline-containing compounds, and N-acetyl aspartate using magnetic resonance spectroscopy; and fractional anisotropy using MRI. Study findings have contributed to a greater understanding of neuroimmune function in the pathophysiology of SUDs, including its temporal dynamics (i.e., acute versus chronic substance use) and new targets for SUD treatment.


Subject(s)
Substance-Related Disorders , Humans , Substance-Related Disorders/diagnostic imaging , Substance-Related Disorders/metabolism , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/pathology , Positron-Emission Tomography , Neuroimaging/methods , Receptors, GABA/metabolism , Receptors, GABA/analysis , Brain/diagnostic imaging , Brain/metabolism , Magnetic Resonance Imaging , Inflammation/diagnostic imaging
20.
ACS Nano ; 18(21): 13836-13848, 2024 May 28.
Article in English | MEDLINE | ID: mdl-38753820

ABSTRACT

Advanced in vivo imaging techniques have facilitated the comprehensive visual exploration of animal biological processes, leading to groundbreaking discoveries such as the glymphatic system. However, current limitations of macroscopic imaging techniques impede the precise investigation of physiological parameters regulating this specialized lymphatic transport system. While NIR-II fluorescence imaging has demonstrated advantages in peripheral lymphatic imaging, there are few reports regarding its utilization in the glymphatic system. To address this, a noninvasive transcranial macroscopic NIR-II fluorescence imaging model is developed using a cyanine dye-protein coupled nanoprobe. NIR-II imaging with high temporal and spatial resolution reveals that hypothermia can increase the glymphatic influx by reducing the flow rate of cerebrospinal fluid. In addition, respiratory rate, respiratory amplitude, and heart rate all play a role in regulating the glymphatic influx. Thus, targeting the glymphatic influx may alter the trajectory of immune inflammation following brain injury, providing therapeutic prospects for treating brain injury with mild hypothermia.


Subject(s)
Brain Injuries , Glymphatic System , Animals , Glymphatic System/diagnostic imaging , Glymphatic System/metabolism , Brain Injuries/metabolism , Brain Injuries/diagnostic imaging , Brain Injuries/therapy , Mice , Optical Imaging , Hypothermia/metabolism , Neuroinflammatory Diseases/diagnostic imaging , Neuroinflammatory Diseases/metabolism , Infrared Rays , Fluorescent Dyes/chemistry , Male , Hypothermia, Induced , Mice, Inbred C57BL , Carbocyanines/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL